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Abstract: Chronic hepatitis is a clinical and
pathological syndrome, which has several
causes and it is characterized by varying
degrees of hepatocellular necrosis and
inflammation. Several systems have been
proposed to evaluate the diagnosis, grading
and staging of chronic hepatitis. A histologic
activity index (HAI) has been developed which
generates a numerical score for liver biopsy
specimens obtained from patients with
chronic hepatitis. The aim of this study was
to evaluate the correlation between HAI and
proliferative activity markers, such as PCNA
and AgNORs in biopsy specimens obtained
from patients with chronic liver disease
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Introduction
Chronic hepatitis is a clinical and pathological
syndrome, which has several causes and it is
characterized by varying degrees of hepatocellular
necrosis and inflammation. Several systems have been
proposed to evaluate the diagnosis, grading and staging
of chronic hepatitis (1–4). A histologic activity index (HAI)
has been developed which generates a numerical score for
liver biopsy specimens obtained from patients with
chronic hepatitis by Knodell et al (5). This consists of four
separate
scores
for
different
components
(periportal±bridging necrosis, intralobular degeneration
and focal necrosis, portal inflammation, and fibrosis) of
the lesions. The evalutation of HAI involves some
disadvantages. The assessment of scores is subjective and
intraobserver and interobserver variability may exist (6).
Proliferating cell nuclear antigen (PCNA) is an
auxillary protein for DNA polymerase delta and has been
recognized as an endogenous histologic marker for
G1/S–phase in the cell cycle (7). There may be a close
correlation between PCNA and cell proliferation.

including chronic hepatitis and cirrhosis.
Mean AgNOR counts and HAI were
significantly higher in the chronic active
hepatitis group than in the chronic persistent
hepatitis group (P<0.001). There was a
correlation between mean AgNOR values and
HAI (p<0.01). There was no correlation
between PCNA LI with conventional histologic
classification, HAI and AgNOR counts
(P>0.05). We suggest that, in contrast to
PCNA, AgNORs may be a useful parameter in
the histologic evaluation, like HAI.
Key Words: AgNORs, PCNA, Histologic
activity index, chronic liver disease.

Nucleolar organizer regions (NORs) are structures of
central importance in the transcription of DNA to
ribosomal DNA (8). Silver stained NORs, reffered to as
AgNORs, appear as black dots in the nucleus (9) and it has
been suggested that the number of AgNOR nuclear dots
may reflect the proliferative activity of cells (10).
The aim of this study was to evaluate the correlation
between HAI and proliferative activity markers, such as
PCNA and AgNORs in biopsy specimens obtained from
patients with chronic liver disease including chronic
hepatitis and cirrhosis.
Materials and Methods
Fifty–four biopsy specimens obtained from patients
with chronic hepatitis/cirrhosis and 4 necroscopy
specimens obtained from normal tissues were studied.
Serum HBsAg/HBeAg was positive in 24 patients,
Anti–HCV was positive in 24 patients and 4 patients were
both HBsAg/HBeAg and Anti–HCV positive.
Tissues were fixed in 10% formalin, embedded in
paraffin wax, and 5 µm thick sections were routinely
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stained with hematoxylin and eosin (H&E). The biopsy
specimens with chronic liver disease were classified
according to the International Group (3): chronic
persistent hepatitis, chronic lobular hepatitis and chronic
active hepatitis. Chronic active hepatitis was divided into
three subgroups: mild, moderate and severe (1).
Cirrhosis was divided into two groups according to the
histologic inflammatory activity; when no significant
histologic inflammatory activity was evident, it was
accepted as inactive cirrhosis (2). Modified Knodell score
was used for the assessment of HAI (2, 4).
Five micrometer paraffin–embedded liver sections
were immunostained with the streptavidin–biotin alkaline
phosphatase system (Biogenex) for PCNA (PCNA–PC10,
monoclonal antibody, mouse, Biogenex). Citrate solution
(Biogenex) was used for antigen retrieval with 5+5
minutes in a microwave (11) before immunostaining. Fast
red was used as chromogen and nuclei that had reacted
with the monoclonal antibody against PCNA were stained
pink to red. The extent of PCNA positivity was evaluated
by determining the percentage of positive nuclei present
in 1000 cells and this percentage was expressed as
Labelling Index (LI).
For AgNOR staining 3 µm sections were cut from
paraffin–embedded biopsy specimens and these sections
were dewaxed and rehydrated. The colloidal silver
staining solution was prepared by dissolving 2% gelatin in
1% aqueous formic acid, which was then mixed in a ratio
of 1:2 by volume with 50% aqueous silver nitrate. The
staining was done at room temperature in darkness for
40 min. After rinsing the sections with distilled water
they were dehydrated and mounted without any
counterstaining. The AgNOR sites were counted in at least
200 randomly selected hepatocytes, using a X1000
objective and AgNORs were identified as recommended
by Crocker et al (12). The mean number of
AgNORs/nucleus was used for the analysis.
The results were expressed as mean values±standard
error of mean (SEM). Pearson coefficient of correlation
and Student’s test were performed and a p value less than
0.05 was considered statistically significant.
Results
The histological findings of the biopsy specimens form
54 patients with chronic liver disease were classifed as
follows: chronic persistent hepatitis 14, chronic lobular
hepatitis 1, chronic active hepatitis 27 (mild 7, moderate
8, severe 12) and cirrhosis 12 (active 8, inactive 4). The
mean HAI, PCNA LI and AgNOR values of the patients
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according to conventional histologic classification are
summarized in the table.
The HAI score and AgNOR values were correlated with
the conventional histological classification as shown in the
table. The mean AgNOR values and HAI score
progressively increased from normal lives tissue to active
cirrhosis. The mean AgNOR counts and HAI were
significantly higher in the chronic active hepatitis group
than in the chronic persistent hepatitis group (P<0.001).
The mean AgNOR value and HAI score of the patients
with inactive cirrhosis were 11.27 and 4.25, respectively.
There was a correlation between mean AgNOR values and
HAI (P<0.01, Table 1).
There was no correlation between PCNA LI with
conventional histologic classification, HAI and AgNOR
counts (P>0.05, Table 1).
The representative examples of AgNOR and PCNA
staining are shown in Figures 1 and 2, respectively.
Table 1.

HAI score, AgNOR counts and PCNA LI in chronic hepatitis
and cirrhosis.

n
Normal
4
CPH
14
CLH
1
CAH
mild
7
moderate
8
severe
12
Cirrhosis
active
8
inactive
4

HAI score

AgNOR

PCNA LI (%)

0
4.36±0.43
5

5.85±0.15
8.32±0.35
8.84

0.62±0.12
11.46±3.37
2.30

7.71±0.18
9.37±0.18
11.25±0.25

9.47±0.64
10.32±0.43
11.50±0.40

8.10±1.54
14.68±3.81
10.00±1.89

13.25±0.88
4.25±0.25

11.86±1.38
11.27±1.81

16.51±4.08
4.15±1.53

CPH : Chronic persistent hepatitis, CLH: Chronic lobular hepatitis, CAH:
Chronic active hepatitis. Results are expressed as mean±standard
error of mean.

Discussion
The correlation between proliferative activity and
AgNORs in human diseases has been shown by many
authors. It has also been suggested that the counting of
AgNORs may be useful both for discriminating between
malign and benign tumors and for estimating histologic
tumor grades in a wide range of malign neoplasms (8, 9,
13–16). The prognastic importance of AgNOR counting
in human liver disease has also been emphasized (13, 17,
18). There are few studies evaluating AgNOR counting in
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human liver disease (13–15, 19) and the results are
contradictory. In the study of Crocker et al (14), the
mean AgNOR values in normal, cirrhotic and
carcinomatous livers were found to be significantly
different and similar in adenoma and chronic active
hepatitis respectively. In their study, there was no overlap
between the ranges of AgNOR counts in normal, cirrhotic
and malignant liver specimens, and quantitation of
staining for AgNORs may be a diagnostically useful
method in liver disease. Zalatnai et al (13) have concluded
that AgNOR counts reflect only the proliferative activity
of a given cell population and they cannot discriminate
between the hyperplastic, benign and neoplastic lesions in
liver disease. Shiro et al (20) have suggested that AgNORs
may be useful for evaluating the progress of

Figure 1.

AgNOR
staining
of
hepatocytes in chronic liver
disease (x1000).

Figure 2.

Intranuclear
for PCNA,
hepatitis,
negative
Redx200).

immunostaining
chronic active
positive (red),
(blue)
(Fast

hepatocellular carcinoma. Derenzini et al (16) have
reported that high AgNOR values are associated with an
increased risk of hepatocellular carcinoma in patients with
chronic liver disease.
As regeneration or repair is one of the consequences
of inflammation, the regenerative growth rate of
hepatocytes could be critical for the prognosis of chronic
liver disease and the degree of inflammation may predict
the regenerative growth rate. To our knowledge, the
correlations between AgNOR values with HAI and PCNA
in chronic liver disease have not been studied previously.
Our study showed that there is a correlation between
mean AgNOR counts and HAI in chronic liver disease,
including chronic persistent hepatitis, chronic active
hepatitis and active cirrhosis. Because assessment of HAI
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does not give any information about proliferative activity
in chronic liver disease, AgNOR counts may be a useful
parameter in the evaluation of liver biopsies. AgNOR
staining is a simple procedure and its price is low; these
may be additional advantages.
Immunostaining of PCNA involves some difficulties.
Monoclonal antibodies such as PC10, 19A2, and 19F4
may be used in the evaluation of PCNA (21–23). The
experience with 19A2 and 19F4 monoclonal antibodies is
limited and most of the commercially available
monoclonal antibody for PNCA assessment is PC10 and it
is the most common antibody used in the literature. PCNA
(PC10) is fixation dependent and its positivity in
proliferating cells is reduced after 48 hours fixation and
is almost eliminated after 72 hours (24). Antigen
retrieval form fixed material using protease treatment
and microwave heating is an alternative method to
increase the sensitivity of PC10 (25). The number of

studies evaluating a correlation between PCNA LI and
inflammatory activity in chronic liver disease is limited
(26, 27). Nakamura et al (26) have shown that PCNA LI
of hepatocytes in chronic persistent hepatitis had a
significant relationship with HAI scores and did not
exceed 3.0%. Our results did not show any relationship
between PCNA LI with conventional histological diagnosis,
HAI score and AgNOR values in patients with chronic liver
disease.
We suggest that, in contrast to PCNA, AgNORs may
be a useful parameter in the histologic evaluation and
response to the treatment in chronic liver disease, like
HAI.
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